BIIB 063

Drug Profile

BIIB 063

Alternative Names: anti-CD40 - Biogen; BIIB063

Latest Information Update: 26 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sjogren's syndrome

Most Recent Events

  • 03 Nov 2017 Pharmacokinetics, pharmacodynamics and immunogenicity data from a phase I SAD trial in Healthy volunteers presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 17 Apr 2017 Biogen terminates phase I trial in healthy volunteers in United Kingdom, due to preclinical safety findings in non-human primates (SC, IV) (NCT02555085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top